| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF1817-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF1750-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | SKM100 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF3689-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-76701SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | FAB1750G | |||
| Carrier Free | MAB1750-SP | |||
| Carrier Free | MAB1750-500 | |||
| Carrier Free | FAB1750V-100UG | |||
| Carrier Free | FAB1750U-100UG | |||
| Carrier Free | FAB1750T-100UG | |||
| Carrier Free | FAB1750S-100UG | |||
| Carrier Free | FAB1750R-100UG | |||
| Carrier Free | FAB1750N-100UG | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Allophycocyanin | FAB1817A | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | FAB1817A | |||
| Carrier Free | MAB1817-SP | |||
| Carrier Free | MAB1817-500 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 1817-TM-050/CF | |||
![N/A TIM-1/KIM-1/HAVCR [HRP]](http://images.novusbio.com/fullsize2/DATA_TIM1_DKM100_ELISA_732.jpg "N/A TIM-1/KIM-1/HAVCR [HRP]")
![N/A TIM-1/KIM-1/HAVCR [HRP]](http://images.novusbio.com/fullsize2/TIM-1_DKM100_ELISA_126.jpg)
![Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - In vitro nephrotoxicity assessment of kidney spheroids. Western blotting analysis of kidney injury markers in kidney spheroids after treatment with 20 uM cisplatin (CPT) or 50 uM cisplatin cyclosporin A (CSA). All data are shown as the means +/- s.e.m. *p < 0.05 compared with control by unpaired Student's t-test. Scale bar, 20 um. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/s41598-019-53855-2) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0016.jpg "<b>Biological Strategies Validation. </b>Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - In vitro nephrotoxicity assessment of kidney spheroids. Western blotting analysis of kidney injury markers in kidney spheroids after treatment with 20 uM cisplatin (CPT) or 50 uM cisplatin cyclosporin A (CSA). All data are shown as the means +/- s.e.m. *p < 0.05 compared with control by unpaired Student's t-test. Scale bar, 20 um. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/s41598-019-53855-2) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - Analysis of human uterus tissue using anti-TIM-1 antibody (3809) at 10 ug/ml.Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 C. A goat anti-rabbit IgG H&L (HRP)at 1/250 was used as secondary. Counter stained with Hematoxylin.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Immunohistochemistry-Paraffin-NBP1-76701-img0013.jpg)
![Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - Loading: 15 ug of NIH/3T3 cell lysates. Antibodies: TIM-1 3809 (8 ug/mL), overnight incubation at 4 C in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0010.jpg)
![<b>Independent Antibodies Validation. </b>Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - Loading: 15 ug of lysates per lane. Antibodies: TIM-1 3809 (8 ug/mL), TIM-13811 (1 ug/mL), beta-actin (1 ug/mL), and GAPDH (0.02 ug/mL), overnightincubation at 4C (3809) or 1h incubation at RT in 5% NFDM/TBST. Secondary:Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0012.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - HeLa cells were transfected with control siRNAs (lane 1) or TIM-1 siRNAs (lane 2) Loading: 15 ug of HeLa whole cell lysates per lane. Antibodies: 3809 (8 ug/mL), 1 hincubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0015.jpg)
![Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - Figure 1 Western Blot Validation in Human Cell LinesLoading: 15 u of lysates per lane.Antibodies: TIM-1 (8 u/mL), overnight incubation at 4; C in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/nbp1-76701_rabbit-polyclonal-tim-1-kim-1-havcr-antibody-2711202420171718.gif)
![Immunocytochemistry/ Immunofluorescence: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - Validation of TIM-1/KIM-1/HAVCR in Human Uterus Cells. Immunofluorescent analysis of 4% paraformaldehyde-fixed human uterus cells labeling TIM-1/KIM-1/HAVCR with at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red). Image showing both membrane and cytoplasmic staining on human uterus cells.](http://images.novusbio.com/fullsize/nbp1-76701_rabbit-polyclonal-tim-1-kim-1-havcr-antibody-271120241937768.jpg)
![N/A TIM-1/KIM-1/HAVCR [HRP]](http://images.novusbio.com/fullsize2/DATA_TIM1_MKM100_ELISA_992.jpg "N/A TIM-1/KIM-1/HAVCR [HRP]")
![N/A TIM-1/KIM-1/HAVCR [HRP]](http://images.novusbio.com/fullsize2/TIM-1_MKM100_ELISA_424.jpg)
![N/A TIM-1/KIM-1/HAVCR [HRP]](http://images.novusbio.com/fullsize2/DATA_TIM1_RKM100_ELISA_1092.jpg "N/A TIM-1/KIM-1/HAVCR [HRP]")
![N/A TIM-1/KIM-1/HAVCR [HRP]](http://images.novusbio.com/fullsize2/TIM-1_RKM100_ELISA_359.jpg)
![Western Blot: TIM-1/KIM-1/HAVCR Antibody [NB100-56421] - Analysis of TIM-1/KIM-1/HAVCR in human brain lysate in the A) absence and B) presence of immunizing peptide, and C) mouse brain lysate using TIM-1 antibody at 2 ug/ml.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NB100-56421-img0003.jpg "Western Blot: TIM-1/KIM-1/HAVCR Antibody [NB100-56421] - Analysis of TIM-1/KIM-1/HAVCR in human brain lysate in the A) absence and B) presence of immunizing peptide, and C) mouse brain lysate using TIM-1 antibody at 2 ug/ml.")
![Immunocytochemistry/Immunofluorescence: TIM-1/KIM-1/HAVCR Antibody [NB100-56421] - Caco-2 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti-TIM-1/KIM-1/HAVCR Antibody at 5 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Immunocytochemistry-Immunofluorescence-NB100-56421-img0004.jpg)
![N/A TIM-1/KIM-1/HAVCR [Biotin]](http://images.novusbio.com/fullsize2/DATA_TIM1_DY3689_ELISA_1973.jpg "N/A TIM-1/KIM-1/HAVCR [Biotin]")